Click here to read an updated version of this article.
Revenues for the quarter grew 26 percent to $24.9 million from $19.7 million for the year-ago period. The company saw growth across its life science and diagnostics businesses, with quantitative PCR being the fastest growing product line in life sciences.
R&D expenses were flat at $2.9 million, compared to $2.8 million during the year-ago period.
The company's net income for the quarter was $2.1 million, or $.1 per share, up 40 percent over last year's income of $1.5 million, or $.08 per share, during the same period. Net income this quarter was positivley impacted by lower interest expenses due to a reduction in outstanding debt.
As of June 30, Stratagene had $5.7 million in cash, cash equivalents, and marketable securities.